Business Wire

SHARJAH-GOVERNMENT

6.6.2022 17:43:08 CEST | Business Wire | Press release

Share
Sir Bu Nair Island, a Safe Haven for Rare Creatures

Around midnight on June 1, a hawksbill turtle landed on the Sir Bu Nair Island. It’s one of the many that began arriving three months ago to nest on the island, bringing the number of nests to more than 300 spread across 27 beaches. The hawksbill turtle lays between 90 to 110 eggs and quietly returns to the sea, leaving eggs to hatch in 50 to 70 days. Part of Sharjah, Sir Bu Nair is situated around 110 km north off the Emirate’s coast.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005699/en/

Declared a nature reserve by a government decree, the island is one of the most important breeding grounds for the endangered hawksbill turtle and features on the International Union for Conservation of Nature list.

The enchanting island, 13 sq km in size, is home to the sooty seagulls (Abu Sannin) and other terns who make thousands of nests in its red soil. Sharjah has strict laws in place to protect all living creatures on the island. Sir Bu Nair is rich in rare green sea turtles, deer, hedgehogs and reptiles. It has also recorded the discovery of the red coat fish.

Rich history

Sir Bu Nair Island has long been preserved in the region’s collective memory of historical events. The British established, during their presence in the region, the first railway in the Emirates, whose relics remain on one side of the beach under the sea.

The island is also known for the sweetness of its waters, which is also fabled to cure rare diseases.

Pottery vessels have been found on the island dating back to the Iron Age, i.e. about 3,500 years ago confirming the continuation of marine activity on the island during the past 35 centuries. There is a cemetery on the island that is known to contain the remains of a number of divers and miners, which represents an important stage in the history of the development of the people living on the banks of the Arabian Gulf.

Mars Island

The island is also known as Al-Jazirah Al-Hamra because of its red terrain and is often compared to the planet Mars. It’s rich in minerals, including sulfur and iron oxide. In the past, railways were used to transport minerals to ships for exporting abroad. Some mines survive to this day.

Known for its sandy beaches and its pristine waters, Sir Bu Nair and its surroundings are rich in coral and marine life, boasting more than 76 types of fish and 40 types of coral reefs.

Emirati poets have long described Sir Bu Nair as “the tear that fell in the waters of the Gulf.” The people of Sharjah have a strong affinity with the island thanks to their historical love of the sea and seafaring traditions. The island had been the seat of generations of pearldivers and fishermen.

International importance

The Sir Bu Nair reserve enjoys strategic global importance and is included in the International Convention on Wetlands because of its rich marine life. It’s included in the preliminary list of UNESCO World Heritage Sites, and an international agreement on the protection and management of sea turtles in the Indian Ocean and Southeast Asia.

HH Sheikh Sultan bin Ahmed Al Qasimi, Deputy Ruler of Sharjah, attended the 22nd Sir Bu Nair Festival, held on June 3-4 to highlight the island's environmental and touristic importance and consolidate the Emirati relationship with their environment and heritage.

Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release

Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye